Key statistics
As of last trade Arbutus Biopharma Corp (I9DN:FRA) traded at 3.23, -23.40% below its 52-week high of 4.22, set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.22 |
---|---|
High | 3.23 |
Low | 3.22 |
Bid | 3.27 |
Offer | 3.38 |
Previous close | 3.19 |
Average volume | 2.73k |
---|---|
Shares outstanding | 189.49m |
Free float | 147.39m |
P/E (TTM) | -- |
Market cap | 655.64m USD |
EPS (TTM) | -0.4259 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 10:43 GMT.
More ▼
Announcements
- Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
- Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
- Arbutus to Present at Jefferies London Healthcare Conference
- Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
- Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
More ▼